

P.O. Box 806  
Pelham, N.Y. 10803  
Telephone: (914) 712-0093  
Fax: (914) 712-0094/5

**Cheryl H. Agris, Ph.D.  
Attorney at Law**

FAX RECEIVED

JUN 21 2002

GROUP 1600

**Fax**

OFFICIAL

To: Examiner J. Roark From: Cheryl Agris  
Fax: 1-703-305-3014 Pages: 14  
Phone: \_\_\_\_\_ Date: 6/20/02  
Re: 09/559,264 (5694.200) CC: \_\_\_\_\_

☐ Urgent

☐ For Review

☐ Please Comment

☐ Please Reply

• Comments:

#### NOTICE OF CONFIDENTIALITY

The information contained in and transmitted with this facsimile is subject to the attorney-client privilege, attorney work product, or is confidential and is intended only for the individual or entity designated above. You are hereby notified that any dissemination, distribution, copying, or use of or reliance upon the information contained in and transmitted with this facsimile by or to anyone other than the recipient designated above by the sender is **unauthorized** and **strictly prohibited**. If you have received this facsimile in error or did not receive all pages, please notify Cheryl H. Agris, Ph.D. Attorney at Law at (914) 712-0093 immediately.

Attorney Docket No.: 5694.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Flodgaard et al.

Serial No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: Jessica H. Roark

Confirmation No: 2707

For: Inhibition Of Bradykinin Release

**CERTIFICATE OF FACSIMILE TRANSMISSION**

Commissioner for Patents  
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment/Reply
3. Request for Continued Examination (RCE) Transmittal (in duplicate)

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Jessica H. Roark, Confirmation No: 2707, fax number (703) 305-3014.

Respectfully submitted,

Date: June 20, 2002

  
Cheryl H. Agris, Reg. No. 34,086  
Outside Counsel for Novo Nordisk  
of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

Attorney Docket No.: 5694.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Flodgaard et al.

Serial No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: Jessica H. Roark

Confirmation No: 2707

For: Inhibition Of Bradykinin Release

**AMENDMENT FEE TRANSMITTAL**

Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Final Office Action mailed December 21, 2001.

It is respectfully requested that the time for response to the Final Office Action dated December 21, 2001 be extended for a period of three (3) months from March 21, 2002 to June 21, 2002. The required fee for the extension is estimated to be \$920.


No additional claims fee is required.

In the event that an extension of time is required, Applicants hereby petition for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

Please charge the required extension fees, estimated to be \$920, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: June 20, 2002



Cheryl H. Agris, Reg. No. 34,086  
Outside Counsel for Novo Nordisk  
of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

# 14/B  
gnd  
6/25/02  
PATENT

Attorney Docket No.: 5694.200-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Flodgaard et al.

Application No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: J. Roark

For: Inhibition Of Bradykinin Release

**AMENDMENT UNDER 37 C.F.R. 1.116**Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In response to the Office Action dated December 21, 2001, please consider the following amendments and remarks.

**IN THE CLAIMS**

Please cancel claims 43-52 without prejudice. Please add new claims 53-60:

SVB  
C3  
B1

1 53. (new) A method for preventing or treating a disorder resulting from release of bradykinin and alterations in endothelial cell permeability in a mammal, wherein said mammal produces heparin binding protein (HBP) that (i) is proteolytically inactive; (ii) is stored in the azurophil granules of polymorphonuclear leukocytes; (iii) is a chemoattractant for monocytes and/or activates monocytes; (iv) has at least about an 80% identity with the amino acid sequence set forth in SEQ ID NO:1; (v) interacts with kininogen resulting in release of bradykinin and (vi) induces alterations in endothelial cell permeability in said mammal, said method comprising administering to said mammal in need thereof, an amount of an anti-

V